The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has McKesson (MCK) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.McKesson is one of 998 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual s ...

Core Insights - Zacks Premium provides various tools to help investors make informed decisions and invest confidently in the stock market [1][2] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [3] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E and Price/Sales [4] - The Growth Score emphasizes a company's financial health and future growth potential, analyzing projected and historical earnings and cash flow [5] - The Momentum Score helps investors capitalize on price trends by evaluating recent price changes and earnings estimate shifts [6] - The VGM Score combines all three Style Scores, providing a comprehensive assessment of stocks based on value, growth, and momentum [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8][9] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [11] Stock Highlight: McKesson Corporation - McKesson Corporation, a healthcare services and IT company, holds a Zacks Rank of 2 (Buy) and a VGM Score of A, making it a strong candidate for growth investors [13] - The company is projected to experience year-over-year earnings growth of 12.6% for the current fiscal year, supported by positive earnings estimate revisions from analysts [14]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates can be challenging due to associated risks and volatility [1] Group 1: Company Overview - McKesson (MCK) is highlighted as a recommended growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 16%, with projected EPS growth of 12.5% this year, surpassing the industry average of 8.2% [4] Group 2: Key Growth Metrics - The asset utilization ratio for McKesson is 4.95, indicating that the company generates $4.95 in sales for every dollar in assets, significantly higher than the industry average of 0.77 [5] - McKesson's sales are expected to grow by 13% this year, compared to the industry average of 3.2% [6] Group 3: Earnings Estimate Revisions - There is a positive trend in earnings estimate revisions for McKesson, with the current-year earnings estimates increasing by 1.7% over the past month [7] Group 4: Investment Positioning - McKesson has achieved a Growth Score of A and a Zacks Rank of 2, positioning it well for potential outperformance in the growth stock category [9]

Company Performance - McKesson (MCK) has returned approximately 26.6% since the beginning of the calendar year, outperforming the Medical sector, which has lost about 4.9% on average [4] - McKesson holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, with the consensus estimate for full-year earnings having increased by 1.4% over the past quarter [3] - McKesson belongs to the Medical - Dental Supplies industry, which includes 14 companies and currently ranks 84 in the Zacks Industry Rank, with this group having lost about 1.9% year-to-date [5] Industry Comparison - The Medical sector consists of 999 individual stocks and currently holds a Zacks Sector Rank of 4, which is based on the average Zacks Rank of the individual stocks within the sector [2] - Another stock in the Medical sector, Adagene Inc. Sponsored ADR (ADAG), has a year-to-date return of 4.8% and also holds a Zacks Rank of 2 (Buy), with its consensus EPS estimate increasing by 7.9% over the past three months [4][5] - The Medical - Biomedical and Genetics industry, which includes Adagene, has 503 stocks and is ranked 75, with this industry having moved -2.9% since the beginning of the year [6]

《财富》指出，今年上榜的 500 家公司共创造了创纪录的 19.9 万亿美元（IT之家注：现汇率约合 143.29 万亿元人民币）营收和 1.87 万亿美元（现汇率约合 13.47 万亿元人民币）利润，2024 财年的入 榜门槛提升到 74 亿美元（现汇率约合 532.85 亿元人民币），相较 2023 年同比增长了 4%。 值得关注的是，今年榜单显示出医疗保健行业的强劲势头：医疗保健行业共创造了 3 万亿美元营收，在 前 25 名中占据了 8 席。相比之下，30 年前的 1995 年，前 25 名中还没有一家医疗保健公司。 IT之家 6 月 3 日消息，2025 年《财富》500 强榜单现已正式公布，沃尔玛和亚马逊连续第六年稳居榜单 前两名，而苹果则再次名列前茅，谷歌母公司 Alphabet 则成为前十名榜单中最赚钱的公司，IT之家附 相应榜单前十名如下： 参考相应榜单，苹果今年位列榜单第 4 名，整体表现保持了过去十年的稳定状态。自 2016 年以来，苹 果一直在第 3 名和第 4 名之间交替，与联合健康集团（UnitedHealth Group）、埃克森美孚（Exxon Mobil）、伯克希尔・哈撒韦（ ...

Core Insights - McKesson (MCK) and Cardinal Health (CAH) are major players in the U.S. healthcare distribution sector, benefiting from consistent demand and long-term industry trends [1][2] - Investors are evaluating which company presents a stronger investment opportunity amid evolving healthcare regulations and inflationary pressures [2] Financial Performance - McKesson reported Q4 fiscal 2025 adjusted EPS of $10.12, exceeding the Zacks Consensus Estimate of $9.81 by 3.2%, with a year-over-year improvement of 63.8% [3] - Cardinal Health reported Q3 fiscal 2025 adjusted EPS of $2.35, surpassing the Zacks Consensus Estimate of $2.15 by 9.3%, with a year-over-year increase of 12.4% [4] Estimates Comparison - The Zacks Consensus Estimate for McKesson's fiscal 2026 sales and EPS indicates a year-over-year improvement of 12.4% and 12.3%, respectively, with EPS estimates improving by 1.4% over the past 60 days [5] - The Zacks Consensus Estimate for Cardinal Health's 2025 sales suggests a year-over-year decline of 1.7%, while EPS is expected to improve by 7.8%, with EPS estimates increasing by 2.3% over the past 30 days [8] Strategic Positioning - McKesson's diversification into higher-margin areas such as oncology and biopharma services supports margin stability and positions the company well for future growth [11] - McKesson's recent earnings report highlighted solid revenue growth, stable margins, and robust free cash flow, alongside consistent shareholder returns through share repurchases and dividend increases [12] - Cardinal Health is focusing on efficiency gains and cost controls while expanding its higher-growth medical segment, which is expected to drive growth [15] - Cardinal Health's first-quarter performance showed strong revenue growth and improving profitability due to effective cost-saving initiatives [16] Price Performance - Year-to-date, McKesson shares have increased by 25.7%, while Cardinal Health shares have surged by 29.2%, driven by rising demand for drug retailing, particularly GLP-1 drugs [17] Investment Outlook - Both companies currently hold a Zacks Rank 3 (Hold), complicating the investment decision [18] - McKesson's style score of 'A' indicates strong growth prospects and attractive valuation, while Cardinal Health's style score of 'C' reflects attractive valuation but lower growth potential [19] - Based on growth estimates and style scores, McKesson is viewed as a better investment choice at present [19]

Group 1: Brokerage Recommendations - McKesson currently has an average brokerage recommendation (ABR) of 1.47, indicating a rating between Strong Buy and Buy, based on recommendations from 17 brokerage firms, with 76.5% (13 out of 17) being Strong Buy [2][5] - Despite the positive ABR, relying solely on this information for investment decisions may not be advisable, as studies show brokerage recommendations often lack success in guiding investors towards stocks with significant price appreciation [5][10] - Analysts from brokerage firms tend to exhibit a strong positive bias in their ratings, issuing five "Strong Buy" recommendations for every "Strong Sell" [6][10] Group 2: Zacks Rank vs. ABR - The Zacks Rank is a proprietary stock rating tool that classifies stocks into five groups based on earnings estimate revisions, providing a more reliable indicator of near-term price performance compared to ABR [8][11] - Unlike ABR, which is based solely on brokerage recommendations and may not be up-to-date, the Zacks Rank reflects timely changes in earnings estimates, making it a more accurate predictor of future price movements [9][12] - The Zacks Consensus Estimate for McKesson has increased by 2% over the past month to $37.10, indicating growing optimism among analysts regarding the company's earnings prospects [13] Group 3: Investment Outlook for McKesson - The recent change in the consensus estimate, along with other factors, has resulted in a Zacks Rank 2 (Buy) for McKesson, suggesting a favorable investment outlook [14]

Core Insights - Mr. Mavroudis is a professional portfolio manager with expertise in managing institutional and private portfolios focusing on risk management and financial market analysis [1] - He has successfully navigated major crises, including the COVID-19 pandemic and the PSI, demonstrating resilience in portfolio management [1] - Mr. Mavroudis is the CEO of FAST FINANCE Investment Services, a registered company by the Hellenic Capital Market Commission, indicating a strong regulatory compliance [1] Company Profile - FAST FINANCE Investment Services is a registered Greek company specializing in investment services, highlighting its credibility in the financial market [1] - The company focuses on restructuring investment portfolios based on prevailing market conditions and client needs, showcasing a client-centric approach [1] Professional Background - Mr. Mavroudis holds multiple advanced degrees, including an MSc in Financial and Banking Management, an LLM in Law, and a BSc in Economics, indicating a strong educational foundation [1] - He is certified in various financial disciplines, including portfolio management and derivatives, which enhances his expertise in the financial sector [1] Engagement and Contribution - By writing on Seeking Alpha, Mr. Mavroudis aims to engage with a community of investors and market enthusiasts, fostering knowledge sharing and mutual growth [1] - His daily articles and appearances as a commentator reflect his active involvement in the financial media landscape [1]

Core Viewpoint - McKesson Corporation plans to spin off its Medical-Surgical Solutions segment into an independent company, referred to as NewCo, to enhance shareholder value and focus on strategic growth priorities in its remaining segments [1][2][4]. Deal Overview - The spin-off is part of McKesson's disciplined portfolio management strategy, which has previously included significant divestitures that unlocked shareholder value [2]. - The Medical-Surgical Solutions segment accounts for only 3.2% of McKesson's total revenue, with FY25 revenue around $11.4 billion, and has experienced sluggish growth since 2020 [4][17]. Financial Performance - For FY25, McKesson reported consolidated revenues of $359.1 billion, a 16.2% increase year-over-year from $309.0 billion in FY24 [12]. - In 4Q25, revenues reached $90.8 billion, up 18.9% year-over-year, driven by growth in the U.S. Pharmaceutical segment [10]. - Net income for FY25 was $3.3 billion, a 9.8% increase year-over-year, while adjusted net income was $4.2 billion, up 15.1% [12]. Strategic Focus Post-Spin-Off - After the spin-off, McKesson will concentrate on higher growth and higher margin opportunities in Oncology and Biopharma Solutions [3]. - The company has made recent acquisitions, including Rx Savings Solutions and plans to acquire a controlling stake in Core Ventures, to strengthen its core operations [3]. Long-Term Growth Targets - McKesson reaffirms its long-term adjusted earnings per diluted share growth target of 12% to 14% and updates the U.S. Pharmaceutical segment's long-term adjusted segment operating profit growth target to 6% to 8% [13][14].

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with McKesson (MCK) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [1][2]. Group 1: Earnings Growth - McKesson has a historical EPS growth rate of 16%, with projected EPS growth of 12% for the current year, significantly outperforming the industry average of 7.5% [5]. Group 2: Asset Utilization - The company boasts an impressive asset utilization ratio of 4.95, indicating it generates $4.95 in sales for every dollar in assets, compared to the industry average of 0.76, showcasing superior efficiency [6]. Group 3: Sales Growth - McKesson's sales are expected to grow by 12% this year, far exceeding the industry average growth rate of 2.1%, highlighting its strong sales performance [7]. Group 4: Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for McKesson, with the Zacks Consensus Estimate for the current year increasing by 2% over the past month, indicating favorable market sentiment [9]. Group 5: Overall Assessment - McKesson has achieved a Growth Score of A and holds a Zacks Rank of 2, suggesting it is a solid choice for growth investors and a potential outperformer in the market [11].